This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

General Anesthesia Drugs Market

Market Insights on General Anesthesia Drugs covering sales outlook, demand forecast & up-to-date key trends

General Anesthesia Drugs Market by Drug Class, Route of Administration, End User & Region - Forecast 2022 – 2032

General Anesthesia Drugs Market Snapshot (2022-2032)

[182 Pages Report] The general anesthesia drugs market is expected to enjoy a valuation of US$ 4.7 Bn by the end of the year 2022, and further expand at a CAGR rate of 3.4% to reach a valuation of US$ 6.7 Bn by the year 2032. According to the recent study by Future Market Insights, Propofol drug class is leading the market with a share of about 25.6% in the year 2021, within the global market.

Market Outlook:

Data Points

Market Insights

Market Value 2021

US$ 4.6 Bn

Market Value 2022

US$ 4.7 Bn

Market Value 2032

US$ 6.7 Bn

CAGR 2022-2032

3.4%

Market Share of Top 5 Countries

63.4%

Key Market Players

Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KgaA, Pfizer, Hospira Inc., Aspen Pharmacare Holdings Limited, Hikama Pharmaceuticals plc, Abbott Laboratories, Avet Pharmaceuticals, Inc, Piramal Enterprises Limited, Par Pharmaceutical, Teva Pharmaceuticals, Viatris/Mylan, Novartis AG, GlaxoSmithKline plc, Gilead Sciences, Inc., Sanofi, Akorn, Apotex, Heritage Pharmaceuticals Inc.

The market for general anesthesia drugs is expected to develop as a result of the widespread use of these drugs in various surgeries as well as the rise in cardiovascular disease and other disorders. The market for general anesthesia drugs is projected to expand due to the development of specific targeted drugs and the availability of technologically advanced drug delivery.

Customize this Report

Let us know your requirement to get
100% FREE customization

Sales Analysis of General Anesthesia Drugs Market from 2014 to 2021 Vs Market Outlook for 2022 to 2032

The market value for general anesthesia drugs is approximately 69.1% of the overall US$ 6.7 Bn of the global anesthesia drug market in 2021.

The sale of general anesthesia drugs expanded at a CAGR of 3.2% from 2014 to 2021, owing to the Increasing prevalence of CRD and CVD.

The objective of general anesthesia is to cause analgesia, autonomic nervous system responses (ANS) and loss of consciousness. General anesthesia drugs injected intravenously are categorized as an IV anaesthetic and are used to induce short surgical procedures.

The prevalence of co-morbidities among older people increases the risk of surgical issues and toxicities associated with general anesthesia will increase the sale of general anesthesia drugs in the forecasting period.

Drugs used for general anesthesia affect the effectiveness and cost of care in these outpatient settings. Hence, the general anesthesia drugs market is expected to expand in the projected period.

Manufacturers are focused on developing novel aesthetic drugs to sustain in the market. Additionally, manufacturers often engage in collaboration agreements and various licensing to assure the global accessibility of their products.

General Anesthesia Drugs Market Download Report Brochure

What are the Key Opportunities for the General Anesthesia Drugs Manufacturers?

An increase in the geriatric population is associated with an increase in chronic diseases that often require surgeries. For instance, as per the report published by World Health Organization on 4 October 2021, one in six individuals on the earth will be 60 or older by 2030. At this point, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. Thus, with an increasing old-age population, a larger number of surgeries are performed and there is high demand for anesthesia drugs.

The cost of healthcare expenditure is increasing in developing and developed countries. Anesthesia is generally covered by health insurance for all medical procedures. For patients with medical insurance, the out-of-pocket cost for anesthesia is around 10% to 50%. Thus, health insurance is beneficial for the management of anesthesia.

Ambulatory anesthesia offers quick recovery from general anesthesia drugs, patients can leave the hospital earlier while also offering massive benefits to third-party payers, hospitals, healthcare providers, and patients. Furthermore, due to ongoing advancements in general anesthesia drugs and various techniques, as well as the widespread availability of short-acting anaesthetics with few side effects, the number of ambulatory surgeries has been rising exponentially.

Additionally, the market for general anesthesia drugs is projected to expand due to the development of specific targeted drugs and the availability of technologically sophisticated drug delivery devices.

Furthermore, the market for general anesthesia drugs is anticipated to generate significant revenue due to the number of clinical trials for the development of general anesthesia drugs and expanding portfolio of the general anesthesia drugs and about specific indications.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Factors Restraining Demand for General Anesthesia Drugs?

Side effects of drugs continue to include amnesia, respiratory depression, elevation in blood pressure and heart rate, and even hallucinations. For instance, drowsiness, vomiting and post-surgery nausea associated with opioid-containing anesthesia make it more difficult for the patient to recover. This restraining factor will hinder the market expansion of the general anesthesia drugs market in future.

Post-surgery Effects of anesthesia drugs after surgery the recovery time is very critical as the patient may suffer some irreversible physical damage. Hence, patients are kept under clinical observation until consciousness is recovered.

Vomiting, nausea, irregularity in heart rhythm, body temperature, respiratory rate, sore throat, and irritation in the respiratory system are among the major shortcomings associated with general anesthesia drugs which badly impact the market.

Complications arising from general anaesthetic drugs can be extensive, ranging from allergic reactions to the inefficacy of drugs. Although fatal complications are rare, common complications such as allergic reactions, cardiovascular collapse, drug interactions, prolonged apnoea, respiratory depression, jaundice, and anesthesia awareness are likely to occur while surgery.

Country-wise Insights

What Makes U.S. a Highly Lucrative Market for General Anesthesia Drugs?

U.S. holds approximately 95.5% share in the North American general anesthesia drugs market in 2021 and is projected to display growth at a lucrative CAGR rate of 2.4% during the forecast period.

In the U.S plastic surgery is common in adults, especially in women. The U.S is the highest country in terms of plastic and cosmetic surgeries. Furthermore, plastic surgeries further required general anesthesia drugs while surgery will boost the market expansion of genres of anesthesia drugs in the country. Over 15 million cosmetic surgery treatments are performed annually in the US. For instance, according to, the Cleveland Clinic adults between the ages of 40 and 54 are more likely to have plastic surgeries, especially, since 92% of cosmetic surgery patients are women.

What Makes the China a Large Market for General Anesthesia Drugs?

China is the second largest economic country with a market share of 18% in the global market in 2021.

In china cancer cases are rising globally will be a further need for general anesthesia drugs for treatment. For instance, report published by the National Library of Medicine, on 9 February 2022, In China, there will be 3,210,000 cancer fatalities and 4,820,000 new cancer cases 2022.

What is the Outlook of Germany in the General Anesthesia Drugs Market?

Germany holds approximately 22% share in the European market in 2021 and is projected to display growth at a lucrative CAGR rate during the forecast period.

Factors influencing the expansion of general anaesthetic medications in Germany are rapid growth in the geriatric population, rising prevalence of chronic diseases, and increasing healthcare expenditure. For instance, a report published by Statista on 27 July 2022, The largest age group in Germany, with 23 million individuals, is 40 to 59. And 18.44 million people aged 65 and beyond made up the next-largest age group.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

Which General Anesthesia Drugs Class is Driving Market Growth?

The Propofol drug class is leading the market with a share of about 25.6% in the year 2021, with a CAGR of about 4.2% in the global market.

Propofol is an anaesthetic agent used intravenously for the maintenance and induction of general anesthesia. It is used to induce unconsciousness. It is also used for the management of refractory status epileptics.

Which Route of Administration is more focussed within General Anesthesia Drugs Market Globally?

Intravenous holds a revenue share of 64.3% in 2021 and is expected to display a gradual growth over the forecast period, with a CAGR of 3.6% by 2032. The drugs are directly administered to the systemic circulation via an intravenous route. When quick absorption is required, IV injections, which involve administering medication into the veins using a needle, are utilized.

Which End User Benefits the Most with the Sales of General Anesthesia Drugs Globally?

Hospitals hold a revenue share of 44.0% in 2021 and are expected to display gradual growth over the forecast period, with a CAGR of 3.8%. The high patient volume in hospitals and the rising number of procedures carried out in these settings can increase the market segment's growth. Surgeons in the hospitals have authority from the government to use anesthesia drugs and it is safe for the patients as they are under observation of health workers.

Competitive Landscape

With several competitors in general anesthesia drugs production sphere, the overall market is highly fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.

  • On June 2019, PAION AG, announced that The European Investment Bank would be providing it with capital in the amount of about $20 million.
  • On 8 October 2020, Fresenius Kabi launches, its first product with an RFID smart label In the U.S. The company's first smart-labelled product is the anesthetic Diprivan® (Propofol) injection, which comes in a 20 mL bottle and uses radio frequency identification (RFID) technology.

Similarly, recent developments related to companies manufacturing general anesthesia drugs have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as per Industry Analysis

Attribute

Details

Forecast Period

2014-2021

Historical Data Available for

2022-2032

Market Analysis

US$ Bn for Value

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa

Key Countries Covered

U.S., Canada, Brazil, Mexico, Argentina, U.K., Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, and South Africa

Key Market Segments Covered

Drug Class, Route of Administration, End User and Region

Key Companies Profiled

  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE & Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals plc
  • Abbott Laboratories
  • Avet Pharmaceuticals, Inc
  • Piramal Enterprises Limited
  • Par Pharmaceutical
  • Teva Pharmaceuticals
  • Viatris/Mylan
  • Novartis AG
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc.
  • Sanofi
  • Akorn
  • Apotex
  • Heritage Pharmaceuticals Inc.

Pricing

Available upon Request

Key Market Segments Covered in General Anesthesia Drugs Industry Research

By Drug Class:

  • Propofol
  • Sevoflurane
  • Dexmedetomidine
  • Desflurane
  • Remifentanil
  • Midazolam
  • Others – (Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental etc.)

By Route of Administration:

  • Intravenous Anesthesia
  • Inhaled Anesthesia

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global general anesthesia drugs market is worth around US$ 4.6 Bn in 2021 and is expected to present high growth at a CAGR rate of 3.4% by the end of the forecast period.

The general anesthesia drugs market is expected to reach US$ 6.7 Bn by the end of 2032, with sales revenue anticipated to grow at 3.4% CAGR.

The U.S., China, U.K., Japan, and Germany are expected to drive demand for the general anesthesia drugs industry.

Baxter International Inc., AstraZeneca, AbbVie Inc., B. Braun Melsungen AG, Fresenius SE & Co. KgaA, Pfizer, Hospira Inc., Aspen Pharmacare Holdings Limited are some of the key players within the general anesthesia drugs market space.

General anesthesia drugs are mostly produced in the U.S. and China. This region's market expands more rapidly than the rest of the world.

One of the major markets for general anesthesia drugs is North America, with market share of about 29.6% in the year 2021.

Increase in the incidence of CVD, CRD, accidents, emergency surgeries and increase in research and development by the manufacturers, good product stability and specificity are some of the key trends in the general anesthesia drugs market.

From 2012-2021, the general anesthesia drugs market has expanded at the rate of 3.2%.

Japan accounts for about 25.1% of market share in 2021 in the East Asian general anesthesia drugs market.

Demand for general anesthesia drugs in Europe is expected to register a growth of 3.0% over the next ten years

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage/ Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Development/Innovation Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. New Product Launches

    4.3. PESTEL Analysis

    4.4. Porter’s Analysis

    4.5. Drug Class Features/ USPs

    4.6. Key Promotional Strategies, By Key Manufacturers

    4.7. Regulatory Landscape

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure

        5.1.3. Global Anesthesia Market

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Key Player’s Historic Growth

        5.2.2. Market Consolidation Activities

        5.2.3. New Product Launches / Approvals

        5.2.4. Increasing Demand of General Anesthesia Drugs

        5.2.5. Increasing Awareness Among People

        5.2.6. Increase in the incidence of CVD, CRD, Accidents.

        5.2.7. Rising of Geriatric Population

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis – Impact Assessment

    6.1. COVID-19 and Impact Analysis

        6.1.1. By Drug Class

        6.1.2. By Route of Administration

        6.1.3. By End User

        6.1.4. By Region

    6.2. 2021 Market Scenario

7. Global General Anesthesia Drugs Market Demand Value or Size (US$ Mn) Analysis 2014 – 2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2014 – 2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global General Anesthesia Drugs Market Analysis 2014– 2021 and Forecast 2022–2032, By Drug Class

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2014 – 2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022–2032

        8.3.1. Propofol

        8.3.2. Sevoflurane

        8.3.3. Dexmedetomidine

        8.3.4. Desflurane

        8.3.5. Remifentanil

        8.3.6. Midazolam

        8.3.7. Others

        8.3.8. Others – Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental etc.)

    8.4. Market Attractiveness Analysis By Drug Class

9. Global General Anesthesia Drugs Market Analysis 2014– 2021 and Forecast 2022–2032, By Route of Administration

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) By Route of Administration, 2014 – 2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022–2032

        9.3.1. Intravenous Anesthesia

        9.3.2. Inhaled Anesthesia

    9.4. Market Attractiveness Analysis By Drug Class

10. Global General Anesthesia Drugs Market Analysis 2014 – 2021 and Forecast 2022–2032, By End User

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) By End User, 2014 – 2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032

        10.3.1. Hospitals

        10.3.2. Ambulatory Surgical Centers

        10.3.3. Specialty Clinics

    10.4. Market Attractiveness Analysis By End User

11. Global General Anesthesia Drugs Market Analysis 2014 – 2021 and Forecast 2022–2032, By Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2014 – 2021

    11.3. Current and Future Market Size (US$ Mn) and Forecast by Region, 2022–2032

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. East Asia

        11.3.5. South Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa (MEA)

    11.4. Market Attractiveness Analysis By Region

12. North America General Anesthesia Drugs Market Analysis 2014 – 2021 and Forecast 2022–2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        12.3.1. By Country

            12.3.1.1. U.S.

            12.3.1.2. Canada

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug Class

        12.4.3. By Route of Administration

        12.4.4. By End User

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country Level Analysis & Forecast

        12.8.1. U.S. General Anesthesia Drugs Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Drug Class

                12.8.1.2.2. By Route of Administration

                12.8.1.2.3. By End User

        12.8.2. Canada General Anesthesia Drugs Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Drug Class

                12.8.2.2.2. By Route of Administration

                12.8.2.2.3. By End User

13. Latin America General Anesthesia Drugs Market Analysis 2014 – 2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        13.3.1. By Country

            13.3.1.1. Mexico

            13.3.1.2. Brazil

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By End User

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Class

        13.4.3. By Route of Administration

        13.4.4. By End User

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. Mexico General Anesthesia Drugs Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Drug Class

                13.8.1.2.2. By Route of Administration

                13.8.1.2.3. By End User

        13.8.2. Brazil General Anesthesia Drugs Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Drug Class

                13.8.2.2.2. By Route of Administration

                13.8.2.2.3. By End User

        13.8.3. Argentina General Anesthesia Drugs Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Drug Class

                13.8.3.2.2. By Route of Administration

                13.8.3.2.3. By End User

14. Europe General Anesthesia Drugs Market Analysis 2014 – 2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        14.3.1. By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. U.K.

            14.3.1.5. Spain

            14.3.1.6. BENELUX

            14.3.1.7. Russia

            14.3.1.8. Rest of Europe

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Class

        14.4.3. By Route of Administration

        14.4.4. By End User

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Germany General Anesthesia Drugs Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Drug Class

                14.8.1.2.2. By Route of Administration

                14.8.1.2.3. By End User

        14.8.2. Italy General Anesthesia Drugs Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Drug Class

                14.8.2.2.2. By Route of Administration

                14.8.2.2.3. By End User

        14.8.3. France General Anesthesia Drugs Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Drug Class

                14.8.3.2.2. By Route of Administration

                14.8.3.2.3. By End User

        14.8.4. U.K. General Anesthesia Drugs Market Analysis

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast by Market Taxonomy

                14.8.4.2.1. By Drug Class

                14.8.4.2.2. By Route of Administration

                14.8.4.2.3. By End User

        14.8.5. Spain General Anesthesia Drugs Market Analysis

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast by Market Taxonomy

                14.8.5.2.1. By Drug Class

                14.8.5.2.2. By Route of Administration

                14.8.5.2.3. By End User

        14.8.6. BENELUX General Anesthesia Drugs Market Analysis

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast by Market Taxonomy

                14.8.6.2.1. By Drug Class

                14.8.6.2.2. By Route of Administration

                14.8.6.2.3. By End User

        14.8.7. Russia General Anesthesia Drugs Market Analysis

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast by Market Taxonomy

                14.8.7.2.1. By Drug Class

                14.8.7.2.2. By Route of Administration

                14.8.7.2.3. By End User

15. East Asia General Anesthesia Drugs Market Analysis 2014 – 2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Class

        15.4.3. By Route of Administration

        15.4.4. By End User 

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. China General Anesthesia Drugs Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Drug Class

                15.8.1.2.2. By Route of Administration

                15.8.1.2.3. By End User

        15.8.2. Japan General Anesthesia Drugs Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Drug Class

                15.8.2.2.2. By Route of Administration

                15.8.2.2.3. By End User

        15.8.3. South Korea General Anesthesia Drugs Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Drug Class

                15.8.3.2.2. By Route of Administration

                15.8.3.2.3. By End User

16. South Asia General Anesthesia Drugs Market Analysis 2014 – 2021 and Forecast 2022–2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend by Market Taxonomy, 2014 – 2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Indonesia

            16.3.1.3. Malaysia

            16.3.1.4. Thailand

            16.3.1.5. Rest of South Asia

        16.3.2. By Drug Class

        16.3.3. By Route of Administration

        16.3.4. By End User /p>

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug Class

        16.4.3. By Route of Administration

        16.4.4. By End User ;

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. India General Anesthesia Drugs Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Drug Class

                16.8.1.2.2. By Route of Administration

                16.8.1.2.3. By End User

        16.8.2. Indonesia General Anesthesia Drugs Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Drug Class

                16.8.2.2.2. By Route of Administration

                16.8.2.2.3. By End User

        16.8.3. Malaysia General Anesthesia Drugs Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Drug Class

                16.8.3.2.2. By Route of Administration

                16.8.3.2.3. By End User

        16.8.4. Thailand General Anesthesia Drugs Market Analysis

            16.8.4.1. Introduction

            16.8.4.2. Market Analysis and Forecast by Market Taxonomy

                16.8.4.2.1. By Drug Class

                16.8.4.2.2. By Route of Administration

                16.8.4.2.3. By End User

17. Oceania General Anesthesia Drugs Market 2014-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Drug Class

        17.3.3. By Route of Administration

        17.3.4. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug Class

        17.4.3. By Route of Administration

        17.4.4. By End User

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. Australia General Anesthesia Drugs Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Drug Class

                17.8.1.2.2. By Route of Administration

                17.8.1.2.3. By End User

        17.8.2. New Zealand General Anesthesia Drugs Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Drug Class

                17.8.2.2.2. By Route of Administration

                17.8.2.2.3. By End User

18. Middle East and Africa (MEA) General Anesthesia Drugs Market Analysis 2014 – 2021 and Forecast 2022–2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        18.3.1. ;By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Turkey

            18.3.1.3. South Africa

            18.3.1.4. North Africa

            18.3.1.5. Rest of Middle East and Africa

        18.3.2. By Drug Class

        18.3.3. By Route of Administration

        18.3.4. By End User

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug Class

        18.4.3. By Route of Administration

        18.4.4. By End User

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. GCC Countries General Anesthesia Drugs Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Drug Class

                18.8.1.2.2. By Route of Administration

                18.8.1.2.3. By End User

        18.8.2. Turkey General Anesthesia Drugs Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Drug Class

                18.8.2.2.2. By Route of Administration

                18.8.2.2.3. By End User

        18.8.3. South Africa General Anesthesia Drugs Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Drug Class

                18.8.3.2.2. By Route of Administration

                18.8.3.2.3. By End Use

        18.8.4. North Africa General Anesthesia Drugs Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Drug Class

                18.8.4.2.2. By Route of Administration

                18.8.4.2.3. By End User

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players (%)

    19.3. Market Presence Analysis

        19.3.1. By Regional Footprint of Players

        19.3.2. Product Footprint of Players

        19.3.3. Channel Footprint of Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Competition Deep Dive

        20.3.1. Baxter International Inc.

            20.3.1.1. Overview

            20.3.1.2. Drug Class Portfolio

            20.3.1.3. Key Financials

            20.3.1.4. SWOT Analysis

            20.3.1.5. Key Developments

            20.3.1.6. Sales Footprint

            20.3.1.7. Strategy Overview

                20.3.1.7.1. Marketing Strategy

                20.3.1.7.2. Product Strategy

                20.3.1.7.3. Channel Strategy

        20.3.2. AstraZeneca

            20.3.2.1. Overview

            20.3.2.2. Drug Class Portfolio

            20.3.2.3. Key Financials

            20.3.2.4. SWOT Analysis

            20.3.2.5. Key Developments

            20.3.2.6. Sales Footprint

            20.3.2.7. Strategy Overview

                20.3.2.7.1. Marketing Strategy

                20.3.2.7.2. Product Strategy

                20.3.2.7.3. Channel Strategy

        20.3.3. AbbVie Inc.

            20.3.3.1. Overview

            20.3.3.2. Drug Class Portfolio

            20.3.3.3. Key Financials

            20.3.3.4. SWOT Analysis

            20.3.3.5. Key Developments

            20.3.3.6. Sales Footprint

            20.3.3.7. Strategy Overview

                20.3.3.7.1. Marketing Strategy

                20.3.3.7.2. Product Strategy

                20.3.3.7.3. Channel Strategy

        20.3.4. B. Braun Melsungen AG

            20.3.4.1. Overview

            20.3.4.2. Drug Class Portfolio

            20.3.4.3. Key Financials

            20.3.4.4. SWOT Analysis

            20.3.4.5. Key Developments

            20.3.4.6. Sales Footprint

            20.3.4.7. Strategy Overview

                20.3.4.7.1. Marketing Strategy

                20.3.4.7.2. Product Strategy

                20.3.4.7.3. Channel Strategy

        20.3.5. Fresenius SE & Co. KgaA

            20.3.5.1. Overview

            20.3.5.2. Drug Class Portfolio

            20.3.5.3. Key Financials

            20.3.5.4. SWOT Analysis

            20.3.5.5. Key Developments

            20.3.5.6. Sales Footprint

            20.3.5.7. Strategy Overview

                20.3.5.7.1. Marketing Strategy

                20.3.5.7.2. Product Strategy

                20.3.5.7.3. Channel Strategy

        20.3.6. Pfizer

            20.3.6.1. Overview

            20.3.6.2. Drug Class Portfolio

            20.3.6.3. Key Financials

            20.3.6.4. SWOT Analysis

            20.3.6.5. Key Developments

            20.3.6.6. Sales Footprint

            20.3.6.7. Strategy Overview

                20.3.6.7.1. Marketing Strategy

                20.3.6.7.2. Product Strategy

                20.3.6.7.3. Channel Strategy

        20.3.7. Hospira Inc.

            20.3.7.1. Overview

            20.3.7.2. Drug Class Portfolio

            20.3.7.3. Key Financials

            20.3.7.4. SWOT Analysis

            20.3.7.5. Key Developments

            20.3.7.6. Sales Footprint

            20.3.7.7. Strategy Overview

                20.3.7.7.1. Marketing Strategy

                20.3.7.7.2. Product Strategy

                20.3.7.7.3. Channel Strategy

        20.3.8. Aspen Pharmacare Holdings Limited

            20.3.8.1. Overview

            20.3.8.2. Drug Class Portfolio

            20.3.8.3. Key Financials

            20.3.8.4. SWOT Analysis

            20.3.8.5. Key Developments

            20.3.8.6. Sales Footprint

            20.3.8.7. Strategy Overview

                20.3.8.7.1. Marketing Strategy

                20.3.8.7.2. Product Strategy

                20.3.8.7.3. Channel Strategy

        20.3.9. Hikama Pharmaceuticals plc

            20.3.9.1. Overview

            20.3.9.2. Drug Class Portfolio

            20.3.9.3. Key Financials

            20.3.9.4. SWOT Analysis

            20.3.9.5. Key Developments

            20.3.9.6. Sales Footprint

            20.3.9.7. Strategy Overview

                20.3.9.7.1. Marketing Strategy

                20.3.9.7.2. Product Strategy

                20.3.9.7.3. Channel Strategy

        20.3.10. Abbott Laboratories

            20.3.10.1. Overview

            20.3.10.2. Drug Class Portfolio

            20.3.10.3. Key Financials

            20.3.10.4. SWOT Analysis

            20.3.10.5. Key Developments

            20.3.10.6. Sales Footprint

            20.3.10.7. Strategy Overview

                20.3.10.7.1. Marketing Strategy

                20.3.10.7.2. Product Strategy

                20.3.10.7.3. Channel Strategy

        20.3.11. Avet Pharmaceuticals, Inc

            20.3.11.1. Overview

            20.3.11.2. Drug Class Portfolio

            20.3.11.3. Key Financials

            20.3.11.4. SWOT Analysis

            20.3.11.5. Key Developments

            20.3.11.6. Sales Footprint

            20.3.11.7. Strategy Overview

                20.3.11.7.1. Marketing Strategy

                20.3.11.7.2. Product Strategy

                20.3.11.7.3. Channel Strategy

        20.3.12. Piramal Enterprises Limited

            20.3.12.1. Overview

            20.3.12.2. Drug Class Portfolio

            20.3.12.3. Key Financials

            20.3.12.4. SWOT Analysis

            20.3.12.5. Key Developments

            20.3.12.6. Sales Footprint

            20.3.12.7. Strategy Overview

                20.3.12.7.1. Marketing Strategy

                20.3.12.7.2. Product Strategy

                20.3.12.7.3. Channel Strategy

        20.3.13. Par Pharmaceutical

            20.3.13.1. Overview

            20.3.13.2. Drug Class Portfolio

            20.3.13.3. Key Financials

            20.3.13.4. SWOT Analysis

            20.3.13.5. Key Developments

            20.3.13.6. Sales Footprint

            20.3.13.7. Strategy Overview

                20.3.13.7.1. Marketing Strategy

                20.3.13.7.2. Product Strategy

                20.3.13.7.3. Channel Strategy

        20.3.14. Teva Pharmaceuticals

            20.3.14.1. Overview

            20.3.14.2. Drug Class Portfolio

            20.3.14.3. Key Financials

            20.3.14.4. SWOT Analysis

            20.3.14.5. Key Developments

            20.3.14.6. Sales Footprint

            20.3.14.7. Strategy Overview

                20.3.14.7.1. Marketing Strategy

                20.3.14.7.2. Product Strategy

                20.3.14.7.3. Channel Strategy

        20.3.15. Viatris/Mylan

            20.3.15.1. Overview

            20.3.15.2. Drug Class Portfolio

            20.3.15.3. Key Financials

            20.3.15.4. SWOT Analysis

            20.3.15.5. Key Developments

            20.3.15.6. Sales Footprint

            20.3.15.7. Strategy Overview

                20.3.15.7.1. Marketing Strategy

                20.3.15.7.2. Product Strategy

                20.3.15.7.3. Channel Strategy

        20.3.16. Novartis AG

            20.3.16.1. Overview

            20.3.16.2. Drug Class Portfolio

            20.3.16.3. Key Financials

            20.3.16.4. SWOT Analysis

            20.3.16.5. Key Developments

            20.3.16.6. Sales Footprint

            20.3.16.7. Strategy Overview

                20.3.16.7.1. Marketing Strategy

                20.3.16.7.2. Product Strategy

                20.3.16.7.3. Channel Strategy

        20.3.17. GlaxoSmithKline plc

            20.3.17.1. Overview

            20.3.17.2. Drug Class Portfolio

            20.3.17.3. Key Financials

            20.3.17.4. SWOT Analysis

            20.3.17.5. Key Developments

            20.3.17.6. Sales Footprint

            20.3.17.7. Strategy Overview

                20.3.17.7.1. Marketing Strategy

                20.3.17.7.2. Product Strategy

                20.3.17.7.3. Channel Strategy

        20.3.18. Gilead Sciences, Inc.

            20.3.18.1. Overview

            20.3.18.2. Drug Class Portfolio

            20.3.18.3. Key Financials

            20.3.18.4. SWOT Analysis

            20.3.18.5. Key Developments

            20.3.18.6. Sales Footprint

            20.3.18.7. Strategy Overview

                20.3.18.7.1. Marketing Strategy

                20.3.18.7.2. Product Strategy

                20.3.18.7.3. Channel Strategy

        20.3.19. Sanofi

            20.3.19.1. Overview

            20.3.19.2. Drug Class Portfolio

            20.3.19.3. Key Financials

            20.3.19.4. SWOT Analysis

            20.3.19.5. Key Developments

            20.3.19.6. Sales Footprint

            20.3.19.7. Strategy Overview

                20.3.19.7.1. Marketing Strategy

                20.3.19.7.2. Product Strategy

                20.3.19.7.3. Channel Strategy

        20.3.20. Akorn

            20.3.20.1. Overview

            20.3.20.2. Drug Class Portfolio

            20.3.20.3. Key Financials

            20.3.20.4. SWOT Analysis

            20.3.20.5. Key Developments

            20.3.20.6. Sales Footprint

            20.3.20.7. Strategy Overview

                20.3.20.7.1. Marketing Strategy

                20.3.20.7.2. Product Strategy

                20.3.20.7.3. Channel Strategy

        20.3.21. Apotex

            20.3.21.1. Overview

            20.3.21.2. Drug Class Portfolio

            20.3.21.3. Key Financials

            20.3.21.4. SWOT Analysis

            20.3.21.5. Key Developments

            20.3.21.6. Sales Footprint

            20.3.21.7. Strategy Overview

                20.3.21.7.1. Marketing Strategy

                20.3.21.7.2. Product Strategy

                20.3.21.7.3. Channel Strategy

        20.3.22. Heritage Pharmaceuticals Inc.

            20.3.22.1. Overview

            20.3.22.2. Drug Class Portfolio

            20.3.22.3. Key Financials

            20.3.22.4. SWOT Analysis

            20.3.22.5. Key Developments

            20.3.22.6. Sales Footprint

            20.3.22.7. Strategy Overview

                20.3.22.7.1. Marketing Strategy

                20.3.22.7.2. Product Strategy

                20.3.22.7.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 02: Global General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration

Table 03: Global General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By End User

Table 04: Global General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Region

Table 05: North America General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 06: North America General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 07: North America General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration

Table 08: North America General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User

Table 09: Latin America General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 10: Latin America General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 11: Latin America General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration

Table 12: Latin America General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User

Table 13: Europe General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 14: Europe General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 15: Europe General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration

Table 16: Europe General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User

Table 17: East Asia General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 18: East Asia General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 19: East Asia General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration

Table 20: East Asia General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User

Table 21: South Asia General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 22: South Asia General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 23: South Asia General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration

Table 24: South Asia General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User

Table 25: Oceania General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 26: Oceania General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 27: Oceania General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration

Table 28: Oceania General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User

Table 29: Middle East & Africa General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 30: Middle East & Africa General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 31: Middle East & Africa General Anesthesia Drugs Market Analysis 2017–2021 and Forecast 2022–2032By Route of Administration

Table 32: Middle East & Africa General Anesthesia Drugs Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global General Anesthesia Drugs Market Value Analysis, 2017–2021

Figure 02: Global General Anesthesia Drugs Market Forecast & Y-o-Y Growth, 2022–2032

Figure 03: Global General Anesthesia Drugs Market Absolute $ Opportunity (US$ Mn) Analysis, 2021–2032

Figure 04: Global General Anesthesia Drugs Market Value Share (%) Analysis 2022 and 2032, By Drug Class

Figure 05: Global General Anesthesia Drugs Market Y-o-Y Growth (%) Analysis 2021-2032, By Drug Class

Figure 06: Global General Anesthesia Drugs Market Attractiveness Analysis 2022–2032, By Drug Class

Figure 07: Global General Anesthesia Drugs Market Value Share (%) Analysis 2022 and 2032, By Route of Administration

Figure 08: Global General Anesthesia Drugs Market Y-o-Y Growth (%) Analysis 2021-2032, By Route of Administration

Figure 09: Global General Anesthesia Drugs Market Attractiveness Analysis 2022–2032, By Route of Administration

Figure 10: Global General Anesthesia Drugs Market Value Share (%) Analysis 2022 and 2032, By End User

Figure 11: Global General Anesthesia Drugs Market Y-o-Y Growth (%) Analysis 2021-2032, By End User

Figure 12: Global General Anesthesia Drugs Market Attractiveness Analysis 2022–2032, By End User

Figure 13: Global General Anesthesia Drugs Market Value Share (%) Analysis 2022 and 2032, By Region

Figure 14: Global General Anesthesia Drugs Market Y-o-Y Growth (%) Analysis 2021-2032, By Region

Figure 15: Global General Anesthesia Drugs Market Attractiveness Analysis 2022–2032, By Region

Figure 16: North America General Anesthesia Drugs Market Size (US$ Mn) Analysis, 2022E & 2032F

Figure 17: North America General Anesthesia Drugs Market Y-o-Y Analysis, 2022-2032

Figure 18: North America General Anesthesia Drugs Market Value Analysis, 2017–2021

Figure 19: North America General Anesthesia Drugs Market Forecast & Y-o-Y growth, 2022–2032

Figure 20: North America General Anesthesia Drugs Market Value Share, By Drug Class (2022 E)

Figure 21: North America General Anesthesia Drugs Market Value Share, By Route of Administration (2022 E)

Figure 22: North America General Anesthesia Drugs Market Value Share, By End User (2022 E)

Figure 23: North America General Anesthesia Drugs Market Value Share, By Country (2022 E)

Figure 24: North America General Anesthesia Drugs Market Attractiveness Analysis by Drug Class, 2022–2032

Figure 25: North America General Anesthesia Drugs Market Attractiveness Analysis by Route of Administration, 2022–2032

Figure 26: North America General Anesthesia Drugs Market Attractiveness Analysis by End User, 2022–2032

Figure 27: North America General Anesthesia Drugs Market Attractiveness Analysis by Country, 2022–2032

Figure 28: U.S. Market Value Proportion Analysis, 2021

Figure 29: U.S. General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 30: U.S. General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 31: U.S. General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 32: Global Vs. U.S. Growth Comparison

Figure 33: Canada Market Value Proportion Analysis, 2021

Figure 34: Canada General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 35: Canada General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 36: Canada General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 37: Global Vs. Canada. Growth Comparison

Figure 38: Latin America General Anesthesia Drugs Market Size (US$ Mn) Analysis, 2022E & 2032F

Figure 39: Latin America General Anesthesia Drugs Market Y-o-Y Analysis, 2022-2032

Figure 40: Latin America General Anesthesia Drugs Market Value Analysis, 2017–2021

Figure 41: Latin America General Anesthesia Drugs Market Forecast & Y-o-Y growth, 2022–2032

Figure 42: Latin America General Anesthesia Drugs Market Value Share, By Drug Class (2022 E)

Figure 43: Latin America General Anesthesia Drugs Market Value Share, By Route of Administration (2022 E)

Figure 44: Latin America General Anesthesia Drugs Market Value Share, By End User (2022 E)

Figure 45: Latin America General Anesthesia Drugs Market Value Share, By Country (2022 E)

Figure 46: Latin America General Anesthesia Drugs Market Attractiveness Analysis by Drug Class, 2022–2032

Figure 47: Latin America General Anesthesia Drugs Market Attractiveness Analysis by Route of Administration, 2022–2032

Figure 48: Latin America General Anesthesia Drugs Market Attractiveness Analysis by End User, 2022–2032

Figure 49: Latin America General Anesthesia Drugs Market Attractiveness Analysis by Country, 2022–2032

Figure 50: Mexico Market Value Proportion Analysis, 2021

Figure 51: Mexico General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 52: Mexico General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 53: Mexico General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 54: Global Vs Mexico Growth Comparison

Figure 55: Brazil Market Value Proportion Analysis, 2021

Figure 56: Brazil General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 57: Brazil General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 58: Brazil General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 59: Global Vs. Brazil. Growth Comparison

Figure 60: Argentina Market Value Proportion Analysis, 2021

Figure 61: Argentina General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 62: Argentina General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 63: Argentina General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 64: Global Vs Argentina Growth Comparison

Figure 65: Europe General Anesthesia Drugs Market Size (US$ Mn) Analysis, 2022E & 2032F

Figure 66: Europe General Anesthesia Drugs Market Y-o-Y Analysis, 2022-2032

Figure 67: Europe General Anesthesia Drugs Market Value Analysis, 2017–2021

Figure 68: Europe General Anesthesia Drugs Market Forecast & Y-o-Y growth, 2022–2032

Figure 69: Europe General Anesthesia Drugs Market Value Share, By Drug Class (2022 E)

Figure 70: Europe General Anesthesia Drugs Market Value Share, By Route of Administration (2022 E)

Figure 71: Europe General Anesthesia Drugs Market Value Share, By End User (2022 E)

Figure 72: Europe General Anesthesia Drugs Market Value Share, By Country (2022 E)

Figure 73: Europe General Anesthesia Drugs Market Attractiveness Analysis by Drug Class, 2022–2032

Figure 74: Europe General Anesthesia Drugs Market Attractiveness Analysis by Route of Administration, 2022–2032

Figure 75: Europe General Anesthesia Drugs Market Attractiveness Analysis by End User, 2022–2032

Figure 76: Europe General Anesthesia Drugs Market Attractiveness Analysis by Country, 2022–2032

Figure 77: U.K. Market Value Proportion Analysis, 2021

Figure 78: U.K. General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 79: U.K. General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 80: U.K. General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 81: Global Vs. U.K. Growth Comparison

Figure 82: Germany Market Value Proportion Analysis, 2021

Figure 83: Germany General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 84: Germany General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 85: Germany General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 86: Global Vs. Germany Growth Comparison

Figure 87: Italy Market Value Proportion Analysis, 2021

Figure 88: Italy General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 89: Italy General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 90: Italy General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 91: Global Vs. Italy Growth Comparison

Figure 92: France Market Value Proportion Analysis, 2021

Figure 93: France General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 94: France General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 95: France General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 96: Global Vs France Growth Comparison

Figure 97: Spain Market Value Proportion Analysis, 2021

Figure 98: Spain General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 99: Spain General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 100: Spain General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 101: Global Vs Spain Growth Comparison

Figure 102: Russia Market Value Proportion Analysis, 2021

Figure 103: Russia General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 104: Russia General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 105: Russia General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 106: Global Vs Russia Growth Comparison

Figure 107: BENELUX Market Value Proportion Analysis, 2021

Figure 108: BENELUX General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 109: BENELUX General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 110: BENELUX General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 111: Global Vs BENELUX Growth Comparison

Figure 112: East Asia General Anesthesia Drugs Market Size (US$ Mn) Analysis, 2022E & 2032F

Figure 113: East Asia General Anesthesia Drugs Market Y-o-Y Analysis, 2022-2032

Figure 114: East Asia General Anesthesia Drugs Market Value Analysis, 2017–2021

Figure 115: East Asia General Anesthesia Drugs Market Forecast & Y-o-Y growth, 2022–2032

Figure 116: East Asia General Anesthesia Drugs Market Value Share, By Drug Class (2022 E)

Figure 117: East Asia General Anesthesia Drugs Market Value Share, By Route of Administration (2022 E)

Figure 118: East Asia General Anesthesia Drugs Market Value Share, By End User (2022 E)

Figure 119: East Asia General Anesthesia Drugs Market Value Share, By Country (2022 E)

Figure 120: East Asia General Anesthesia Drugs Market Attractiveness Analysis by Drug Class, 2022–2032

Figure 121: East Asia General Anesthesia Drugs Market Attractiveness Analysis by Route of Administration, 2022–2032

Figure 122: East Asia General Anesthesia Drugs Market Attractiveness Analysis by End User, 2022–2032

Figure 123: East Asia General Anesthesia Drugs Market Attractiveness Analysis by Country, 2022–2032

Figure 124: China Market Value Proportion Analysis, 2021

Figure 125: China General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 126: China General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 127: China General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 128: Global Vs. China Growth Comparison

Figure 129: Japan Market Value Proportion Analysis, 2021

Figure 130: Japan General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 131: Japan General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 132: Japan General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 133: Global Vs. Japan Growth Comparison

Figure 134: South Korea Market Value Proportion Analysis, 2021

Figure 135: South Korea General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 136: South Korea General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 137: South Korea General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 138: Global Vs South Korea Growth Comparison

Figure 139: South Asia General Anesthesia Drugs Market Size (US$ Mn) Analysis, 2022E & 2032F

Figure 140: South Asia General Anesthesia Drugs Market Y-o-Y Analysis, 2022-2032

Figure 141: South Asia General Anesthesia Drugs Market Value Analysis, 2017–2021

Figure 142: South Asia General Anesthesia Drugs Market Forecast & Y-o-Y growth, 2022–2032

Figure 143: South Asia General Anesthesia Drugs Market Value Share, By Drug Class (2022 E)

Figure 144: South Asia General Anesthesia Drugs Market Value Share, By Route of Administration (2022 E)

Figure 145: South Asia General Anesthesia Drugs Market Value Share, By End User (2022 E)

Figure 146: South Asia General Anesthesia Drugs Market Value Share, By Country (2022 E)

Figure 147: South Asia General Anesthesia Drugs Market Attractiveness Analysis by Drug Class, 2022–2032

Figure 148: South Asia General Anesthesia Drugs Market Attractiveness Analysis by Route of Administration, 2022–2032

Figure 149: South Asia General Anesthesia Drugs Market Attractiveness Analysis by End User, 2022–2032

Figure 150: South Asia General Anesthesia Drugs Market Attractiveness Analysis by Country, 2022–2032

Figure 151: India Market Value Proportion Analysis, 2021

Figure 152: India General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 153: India General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 154: India General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 155: Global Vs. India Growth Comparison

Figure 156: Indonesia Market Value Proportion Analysis, 2021

Figure 157: Indonesia General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 158: Indonesia General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 159: Indonesia General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 160: Global Vs. Indonesia Growth Comparison

Figure 161: Malaysia Market Value Proportion Analysis, 2021

Figure 162: Malaysia General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 163: Malaysia General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 164: Malaysia General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 165: Global Vs. Malaysia Growth Comparison

Figure 166: Thailand Market Value Proportion Analysis, 2021

Figure 167: Thailand General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 168: Thailand General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 169: Thailand General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 170: Global Vs. Thailand Growth Comparison

Figure 171: Oceania General Anesthesia Drugs Market Size (US$ Mn) Analysis, 2022E & 2032F

Figure 172: Oceania General Anesthesia Drugs Market Y-o-Y Analysis, 2022-2032

Figure 173: Oceania General Anesthesia Drugs Market Value Analysis, 2017–2021

Figure 174: Oceania General Anesthesia Drugs Market Forecast & Y-o-Y growth, 2022–2032

Figure 175: Oceania General Anesthesia Drugs Market Value Share, By Drug Class (2022 E)

Figure 176: Oceania General Anesthesia Drugs Market Value Share, By Route of Administration (2022 E)

Figure 177: Oceania General Anesthesia Drugs Market Value Share, By End User (2022 E)

Figure 178: Oceania General Anesthesia Drugs Market Value Share, By Country (2022 E)

Figure 179: Oceania General Anesthesia Drugs Market Attractiveness Analysis by Drug Class, 2022–2032

Figure 180: Oceania General Anesthesia Drugs Market Attractiveness Analysis by Route of Administration, 2022–2032

Figure 181: Oceania General Anesthesia Drugs Market Attractiveness Analysis by End User, 2022–2032

Figure 182: Oceania General Anesthesia Drugs Market Attractiveness Analysis by Country, 2022–2032

Figure 183: Australia Market Value Proportion Analysis, 2021

Figure 184: Australia General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 185: Australia General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 186: Australia General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 187: Global Vs. Australia Growth Comparison

Figure 188: New Zealand Market Value Proportion Analysis, 2021

Figure 189: New Zealand General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 190: New Zealand General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 191: New Zealand General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 192: Global Vs New Zealand Growth Comparison

Figure 193: Middle East & Africa General Anesthesia Drugs Market Size (US$ Mn) Analysis, 2022E & 2032F

Figure 194: Middle East & Africa General Anesthesia Drugs Market Y-o-Y Analysis, 2022-2032

Figure 195: Middle East & Africa General Anesthesia Drugs Market Value Analysis, 2017–2021

Figure 196: Middle East & Africa General Anesthesia Drugs Market Forecast & Y-o-Y growth, 2022–2032

Figure 197: Middle East & Africa General Anesthesia Drugs Market Value Share, By Drug Class (2022 E)

Figure 198: Middle East & Africa General Anesthesia Drugs Market Value Share, By Route of Administration (2022 E)

Figure 199: Middle East & Africa General Anesthesia Drugs Market Value Share, By End User (2022 E)

Figure 200: Middle East & Africa General Anesthesia Drugs Market Value Share, By Country (2022 E)

Figure 201: Middle East & Africa General Anesthesia Drugs Market Attractiveness Analysis by Drug Class, 2022–2032

Figure 202: Middle East & Africa General Anesthesia Drugs Market Attractiveness Analysis by Route of Administration, 2022–2032

Figure 203: Middle East & Africa General Anesthesia Drugs Market Attractiveness Analysis by End User, 2022–2032

Figure 204: Middle East & Africa General Anesthesia Drugs Market Attractiveness Analysis by Country, 2022–2032

Figure 205: GCC Countries Market Value Proportion Analysis, 2021

Figure 206: GCC Countries General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 207: GCC Countries General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 208: GCC Countries General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 209: Global Vs GCC Countries Growth Comparison

Figure 210: Turkey Market Value Proportion Analysis, 2021

Figure 211: Turkey General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 212: Turkey General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 213: Turkey General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 214: Global Vs. Turkey Growth Comparison

Figure 215: South Africa Market Value Proportion Analysis, 2021

Figure 216: South Africa General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 217: South Africa General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 218: South Africa General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 219: Global Vs. South Africa Growth Comparison

Figure 220: North Africa Market Value Proportion Analysis, 2021

Figure 221: North Africa General Anesthesia Drugs Market Share Analysis (%) By Drug Class, 2021 & 2032

Figure 222: North Africa General Anesthesia Drugs Market Share Analysis (%) By Route of Administration, 2021 & 2032

Figure 223: North Africa General Anesthesia Drugs Market Share Analysis (%) By End User, 2021 & 2032

Figure 224: Global Vs North Africa Growth Comparison

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Injectable Drugs Market

Published : June 2022

Healthcare

Portable Anesthesia Systems Market

Published : October 2017

Healthcare

Analgesics Market

Published : December 2021

Google translate

General Anesthesia Drugs Market